Cargando…

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?

Chronic delta hepatitis is a global health problem. Although a smaller percentage of chronic HBV-infected patients are coinfected with the hepatitis delta virus, these patients have a higher risk of an accelerated progression to fulminant “delta hepatitis”, cirrhosis, hepatic decompensation, and hep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nemteanu, Roxana, Clim, Andreea, Hincu, Corina Elena, Gheorghe, Liliana, Ciortescu, Irina, Plesa, Alina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605217/ https://www.ncbi.nlm.nih.gov/pubmed/37886941 http://dx.doi.org/10.3390/cimb45100498

Ejemplares similares

Replacing the Burden of the Gluten Free Diet: Then, Now, and the Future
por: Nemteanu, Roxana, et al.
Publicado: (2022)

Is There a Time and a Place for the Gluten-Free Diet in Potential Celiac Disease?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab
por: Ciortescu, Irina, et al.
Publicado: (2023)

An Underrated Diagnosis of Superior Mesenteric Artery Syndrome: A Case Report
por: Ciortescu, Irina, et al.
Publicado: (2022)

Making a Comeback: Syphilitic Hepatitis in a Patient with Late Latent Syphilis—Case Report and Review of the Literature
por: Plesa, Alina, et al.
Publicado: (2022)

Predictors of slow responsiveness and partial mucosal recovery in adult patients with celiac disease
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Risk Scores for Prediction of Major Cardiovascular Events in Non-Alcoholic Fatty Liver Disease: A No Man’s Land?
por: Gheorghe, Liliana, et al.
Publicado: (2023)

The Renin-Angiotensin System: The Challenge behind Autoimmune Dermatological Diseases
por: Maranduca, Minela Aida, et al.
Publicado: (2023)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon
por: Mascia, Claudia, et al.
Publicado: (2017)

The expectations of generation Z regarding the university educational act in Romania: optimizing the didactic process by providing feedback
por: Bratu, Mihaela Laura, et al.
Publicado: (2023)

Biliary Hamartoma
por: BARBOI, OANA-BOGDANA, et al.
Publicado: (2013)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens
por: Puenpatom, Amy, et al.
Publicado: (2017)

Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
por: Rosenthal, Elana S., et al.
Publicado: (2016)

Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus
por: Franco, Evelyn J., et al.
Publicado: (2021)

Are we there yet?
por: Wise, Jo Ann
Publicado: (2015)

Are we there yet?
por: Swann, Nicole
Publicado: (2019)

Are we there yet?
por: McCann, Shaun R.
Publicado: (2022)

A chemotherapy-free regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia: are we there yet?
por: Ofran, Yishai
Publicado: (2021)

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals
por: Alexopoulou, Alexandra, et al.
Publicado: (2015)

Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection
por: Salama, Iman Ibrahim, et al.
Publicado: (2022)

Interferon-λ Genetic Variations and Hepatitis C: Yet to be Discovered
por: Keshvari, Maryam, et al.
Publicado: (2014)

Antiviral activities of interferons
por: Stewart, William E., et al.
Publicado: (1979)

Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C
por: Ramamurthy, Narayan, et al.
Publicado: (2018)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal, Sanaa M
Publicado: (2014)

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma
por: Teng, Wei, et al.
Publicado: (2019)

Are we nearly there yet?
por: Battersby, Stephen
Publicado: (2005)

Why Are We Not There Yet?
por: Wenger, Nanette K.
Publicado: (2021)

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
por: Adiwijaya, Bambang S., et al.
Publicado: (2012)

Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C
por: Itakura, Jun, et al.
Publicado: (2020)

Transplantation of Organs from Hepatitis C Virus-Positive Donors under Direct-Acting Antiviral Regimens
por: Zahid, Muhammad Nauman
Publicado: (2022)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals
por: Sung, Pil Soo, et al.
Publicado: (2020)

Interferon-inducible antiviral effectors
por: Sadler, Anthony J., et al.
Publicado: (2008)

Antiviral defense: interferons and beyond
por: Stetson, Daniel B., et al.
Publicado: (2006)

Avian Interferons and Their Antiviral Effectors
por: Santhakumar, Diwakar, et al.
Publicado: (2017)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
por: Toyoda, Hidenori
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_92g1nrjjnrnhbskojmp242s0nj